Andrew Sinclair - 26 Aug 2022 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Role
Director
Signature
/s/ Anish Bhatnagar, Attorney-in-Fact
Issuer symbol
SLNO
Transactions as of
26 Aug 2022
Net transactions value
$0
Form type
4
Filing time
14 Oct 2022, 19:25:50 UTC
Previous filing
01 Jul 2022
Next filing
26 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SLNO Stock option (right to buy) 1,333 26 Aug 2022 Common Stock 1,333 $23.55 Direct F1, F2
holding SLNO Stock option (right to buy) 823 26 Aug 2022 Common Stock 823 $39.45 Direct F1, F3
holding SLNO Stock option (right to buy) 635 26 Aug 2022 Common Stock 635 $51.15 Direct F1, F3
holding SLNO Stock option (right to buy) 2,666 26 Aug 2022 Common Stock 2,666 $33.60 Direct F1, F3
holding SLNO Stock option (right to buy) 2,124 26 Aug 2022 Common Stock 2,124 $15.30 Direct F1, F3
holding SLNO Stock option (right to buy) 2,666 26 Aug 2022 Common Stock 2,666 $2.55 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022.
F2 One forty-eighth (1/48th) of the shares subject to the Option shall vest on the first month anniversary of December 21, 2018 (the "Vesting Commencement Date"), and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person continuing to be a Service Provider through each such date.
F3 All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F4 The shares subject to the Option shall vest on the earlier of the twelve-month anniversary of June 1, 2022 or the day before the next annual stockholder meeting, subject to Reporting Person continuing to be a Service Provider through each such date.

Remarks:

The Reporting Person is no longer deemed to share an indirect pecuniary interest in the securities held by Abingworth Bioventures VII, LP and therefore no longer reports those securities on his Section 16 reports.